KRN7000 Patent

Kyowa Hakko Kirin Company and etc., are the patent owner under United States patent# 5,936,076.  Kyowa Hakko Kirin Company has issued an exclusive worldwide license for research use only, not for use in human to Funakoshi Company, which Funakoshi Company has consent and authority to enforce patent# 5,936,076 by all legal means.  Any entity without the written consent of Kyowa Hakko Kirin Company or Funakoshi Company violating the KRN7000 patent will be subject to financial liability and/or other legal actions.

The following companies have been authorized to sell KRN7000 for research use only:

Avanti Polar Lipids

Cayman Chemical
ProImmune Inc.

All other countries please contact Funakoshi Company by email:


New 7DW8-5 glycolipid


Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch


Meet Funakoshi Company
at the following meetings:

NIH Festival
Bethesda, Maryland
September 14-15, 2017

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

Philadelphia, PA
December 2-6, 2017